Table 1.

Clinical and treatment characteristics.

Variable		Total	No Contracture Group	Contracture Group	p
Number of Patients		59	31 (53%)	28 (47%)
Age	Median (IQR)	47 (43–52.5)	47 (43–54)	47.5 (43.5–52)	0.693
Menopausal Status					0.482
	Pre	33	16 (48%)	17 (52%)
	Post	26	15 (58%)	11 (42%)
ER					0.05
	Positive	42	18 (43%)	24 (57%)
	Negative	12	9 (75%)	3 (25%)
	Missing	5	4 (80%)	1 (20%)
PgR					0.129
	Positive	39	17 (44%)	22 (56%)
	Negative	15	10 (67%)	5 (33%)
	Missing	5	4 (80%)	1 (20%)
Ki67					0.402
	Positive	33	15 (45%)	18 (55%)
	Negative	21	12 (57%)	9 (43%)
	Missing	5	4 (80%)	1 (20%)
HER2					1.0000
	Positive	12	6 (50%)	6 (50%)
	Negative	42	21 (50%)	21 (50%)
	Missing	5	4 (80%)	1 (20%)
Grading					0.293
	I	2	1 (50%)	1 (50%)
	II	21	13 (62%)	8 (38%)
	III	28	11 (39%)	17 (61%)
	Missing	8	6 (75%)	2 (25%)
T					0.571
	1	19	11 (58%)	8 (42%)
	2	24	11 (46%)	13 (54%)
	3	8	3 (37.5%)	5 (62.5%)
	Missing	8	6 (75%)	2 (25%)
N					0.219
	0	9	5 (56%)	4 (44%)
	1	14	10 (71%)	4 (29%)
	2	15	6 (40%)	9 (60%)
	3	14	5 (36%)	9 (64%)
	Missing	7	5 (71%)	2 (29%)
Histological subtype					0.482
	Ductal	42	22 (52%)	20 (48%)
	Other	10	4 (40%)	6 (60%)
	Missing	7	5 (71%)	2 (29%)
Molecular subtype					0.076
	HER2 positive	12	6 (50%)	6 (50%)
	Luminal A	18	11 (61%)	7 (39%)
	Luminal B	16	4 (25%)	12 (75%)
	Triple negative	8	6 (75%)	2 (25%)
	Missing	5	4 (80%)	1 (20%)
Neoadjuvant chemotherapy					0.0599
	Yes	21	12 (57%)	9 (43%)
	No	38	19 (50%)	19 (50%)
Lymphadenectomy					0.449
	Yes	51	25 (49%)	26 (51%)
	No	4	3 (75%)	1 (25%)
	Missing	4	3 (75%)	1 (25%)
Expander or Prosthesis					0.232
	Expander	28	17 (61%)	11 (39%)
	Prosthesis	31	14 (45%)	17 (55%)
Size expander					0.285
	≤ 300 cc	5	4 (80%)	1 (20%)
	300–450 cc	20	11 (55%)	9 (45%)
	> 450 cc	3	2 (67%)	1 (33%)
Size prosthesis					0.092
	≤ 300 cc	5	4 (80%)	1 (20%)
	300–450 cc	12	3 (25%)	9 (75%)
	> 450 cc	13	7 (54%)	6 (46%)
	Missing	1
Months between Reconstruction and RT	Median (IQR)	3 (2–5)	4 (2–7)	3 (1.5–4.5)	0.274